As U.S. scientists ramp up a national effort to evaluate COVID-19 vaccine candidates at clinical trial sites across the country, researchers at Saint Louis University’s Center for Vaccine Development have been tapped to join the historic effort to find a COVID-19 vaccine that can prevent the illness. This month, we will begin enrolling 1000 participants in the first COVID-19 vaccine trial and several additional trials are expected to begin later this year. Researchers say it will be critically important to enroll participants who are likely to be exposed to COVID-19 or those at risk for severe disease from COVID-19, including participants over age 65.
Interested in Volunteering for a COVID-19 Prevention Clinical Study?
The purpose of this screening registry is to create a list of potential volunteers who want to take part in current or future COVID-19 prevention clinical trials. You must be 18 years or older to participate. Participation involves completing a short online survey that includes some personal questions. Your participation is voluntary.
Frequently Asked Questions About COVID-19 Clinical Studies
A: In order to find a vaccine or antibody that works in all kinds of people, it is necessary to test them in all kinds of people. This is especially true for groups of people that have been hardest hit by the COVID-19 pandemic. Protecting the well-being of study volunteers is the greatest responsibility in every study, and the CoVPN works to make sure that our studies follow the highest ethical standards. These studies are done in collaboration with local scientists and researchers and community representatives with oversight by ethics and regulatory groups in each country. Many studies are done in sub-Saharan Africa, Europe, North America, and South America at the same time and we follow the same procedures and international standards no matter where the study takes place.
Frequently Asked Questions About COVID-19 Disease
A: No. People of all ages can be infected by SARS-CoV-2, the virus that causes COVID-19. However, older people and people with some pre-existing health conditions are more at risk of severe illness.
A: COVID-19 can affect anyone, regardless of their race or ethnicity. However, data show that it is disproportionately impacting Black, Latinx, and Native American populations. This is largely due to social and structural factors that impact some communities more than others. These factors include poverty, poor housing conditions, challenges with accessing medical care, and limited resources, among others.
A: No. Antibiotics help stop bacterial infections and are not effective against viruses such as SARS-CoV-2.
A: No. Some people who do get SARS-CoV-2, the virus that causes COVID-19, experience flu-like symptoms. COVID-19 currently has a higher death rate than the flu and appears to be more contagious than the flu. We do not know yet whether COVID-19 will change with the seasons like influenza. In the US, the CDC recommends that everyone aged 6 months and over receive an influenza vaccine every year.
A: Yes. Scientists have found that people who have SARS-CoV-2 and have no symptoms (i.e., asymptomatic) can still pass along SARS-CoV-2 to others. In fact, people infected with SARS-CoV-2 seem to be most infectious before they even show signs and symptoms.
A: The FDA is reviewing many drugs as potential treatments, but nothing has yet been approved to treat or prevent COVID-19. The FDA is also identifying treatments, such as Remdesivir, to help ease the symptoms and help people recover more quickly.
A: Face masks can reduce your chances of getting SARS-CoV-2, but the primary purpose of face masks is to protect others from you in case you are infected, especially if you are not showing symptoms. It is recommended that the public wear cloth masks, including homemade masks, to help prevent transmitting the virus to other people.
A: To date there is no information or evidence to suggest that SARS-CoV-2 can be transmitted by mosquitos. This disease is a respiratory virus spread primarily through droplets when an infected person coughs, sneezes or has discharge from the nose.
A: Vaccines against other diseases do not offer protection against SARS-CoV-2. This is a new virus that will need its own vaccine, and researchers are working on developing a safe and effective one.
A: SARS-CoV-2 can be transmitted in all areas, including hot/humid and cold climates.
A: While gargling with warm saltwater can make a sore throat feel better, it has no effect on SARS-CoV-2.
A: There are simple things you can do to help keep yourself and others healthy. Wash your hands often with soap and water for at least 20 seconds, especially after blowing your nose, coughing, sneezing, going to the bathroom, and before eating or preparing food.
When in public, wear a cloth face mask that covers your mouth and nose. Avoid touching your eyes, nose, and mouth with unwashed hands. Stay home when you are sick. Cover your cough or sneeze with a tissue, then throw the tissue in the trash. Stay 6 feet apart from other people when you are out in public.
A: No. You can help stop COVID-19 by knowing the signs and symptoms, which can include:
Shortness of breath
New loss of taste and/or smell
Seek medical attention immediately if you or someone you have been exposed to has emergency warning signs, including:
Persistent pain or pressure in the chest
New confusion or not able to be woken up (from sleep)
Bluish lips or face
This list of symptoms is not all inclusive and is being updated as new information becomes available. Please consult your medical provider for any other symptoms that are severe or concerning.
Further Information on SARS-CoV-2 and COVID-19
What we know about the virus, SARS-CoV-2, and the disease, COVID-19, is constantly changing. To stay up to date on the most current information, we recommend that you visit the following websites for reliable and accurate information:
- U.S. Epidemic (CDC)
- Racial and Ethnic Disparities with COVID-19 in the U.S. (CDC)
- Global Epidemic (WHO)
Information about how the epidemic is impacting the world (mathematical modeling):